Nicholas Hertz

Nicholas Hertz

Company: Mitokinin

Job title: Chief Scientific Officer & Founder


Decision Making Behind Preclinical Mitochondrial Toxicity Studies 4:00 pm

Mitochondrial toxicity is a major concern of many drugs development projects across disease areas, therapeutic strategies, and drug development. Workshop highlights include: Understand the science-lead decision making across multiple drug development projects Explore the key technologies, tools, and processes to comprehensively demonstrate drug safety early to promote translationRead more

day: Pre-Conference Day

Pharmacological PINK1 activation Ameliorates Pathology in Parkinson’s Disease Models 11:45 am

Improving mitochondrial quality control as a treatment for Parkinson’s and chronic diseases of mitochondrial dysfunction Combining genetically validated targets with small molecules to create a novel therapeutic modalityRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.